Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Minimal residual disease and outcome characteristics in infant KMT2A-germline acute lymphoblastic leukaemia treated on the Interfant-06 protocol

13 Nov 2021

Abstract excerpt

Background The outcome of infants with KMT2A -germline acute lymphoblastic leukaemia (ALL) is superior to that of infants with KMT2A -rearranged ALL but has been inferior to non-infant ALL patients. Here, we describe the outcome and prognostic factors for 167 infants with KMT2A -germline ALL enrolled in the Interfant-06 study. Methods Univariate analysis on prognostic factors (age, white blood cell count at...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Lymphoblastic Leukemia research
Share to Adolescent and Pediatric Healthcare
Share to Childhood Cancer Survivors' Quality of Life

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34785111
DOI: 10.1016/j.ejca.2021.10.004

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Minimal residual disease and outcome characteristics in infant KMT2A-germline acute lymphoblastic leukaemia treated on the Interfant-06 protocolPMID 34785111Read ↗

Clinical Implications of Minimal Residual Disease Detection in Infants With KMT2A-Rearranged Acute Lymphoblastic Leukemia Treated on the Interfant-06 ProtocolSemantic proximity Read ↗

Updates in the biology and therapy for infant acute lymphoblastic leukemiaSemantic proximity Read ↗

Outstanding outcomes in infants with KMT2A-germline acute lymphoblastic leukemia treated with chemotherapy alone: results of the Children’s Oncology Group AALL0631 trialSemantic proximity Read ↗

Clinicopathologic and genetic spectrum of infantile B-lymphoblastic leukemia: a multi-institutional study.Semantic proximity Read ↗

Multiple Lineage Switches in KMT2A Rearranged Infant Leukemia, Responsive to Combination Therapy with CPX-351 and InotuzumabSemantic proximity Read ↗

Molecular characterization and biomarker identification in paediatric B-cell acute lymphoblastic leukaemia.Semantic proximity Read ↗

Outcomes of acute lymphoblastic leukemia with KMT2A (MLL) rearrangement: the MD Anderson experienceSemantic proximity Read ↗

Multi-omics analysis defines highly refractory RAS burdened immature subgroup of infant acute lymphoblastic leukemiaSemantic proximity Read ↗

Crossing Our T’s: An Unusual Presentation of Infantile T-cell LeukemiaSemantic proximity Read ↗

Unraveling the cellular origin and clinical prognostic markers of infant B-cell acute lymphoblastic leukemia using genome-wide analysisSemantic proximity Read ↗

Intra-subtype heterogeneity shapes treatment response in <i>KMT2A</i> -rearranged ALL across all age groupsSemantic proximity Read ↗

KMT2A rearranged acute lymphoblastic leukaemia: Unravelling the genomic complexity and heterogeneity of this high-risk disease.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.